Day: September 7, 2022

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Acceptance Test Procedures (ATP) for the first Protector RG Mk1 Remotely Piloted Aircraft (RPA) system was completed on Aug. 26, 2022. Completion of ATP allows for the official hand-over of the aircraft to the UK Royal Air Force (RAF), the launch customer of the MQ-9B RPA system developed by General Atomics Aeronautical Systems, Inc. (GA-ASI). Protector is a specially configured model of MQ-9B, designed to meet the unique requirements of the RAF.

The International City/County Management Association has adopted a new global engagement strategy to assure their future as the premier resource for local government professionals across the globe

WASHINGTON, Sept. 07, 2022 (GLOBE NEWSWIRE) — The International City/County Management Association (ICMA), announced a new initiative aimed at strengthening local government management practices through a global learning approach. In collaboration with its partners and members throughout the world, ICMA will develop new programs, launch new services, and conduct new research in order to advance effective local government management practices.

“No matter where you are in the world, and regardless of the form of government a nation adopts, local government officials are the ones who have the most direct impact on our daily lives,” said Marc Ott, ICMA executive director and CEO. “This new initiative adopted by our board provides strategic direction as we continue to serve as the leading voice on local government management and administration practices.”

ICMA has a long history of supporting local governments across the globe. Through federal grant programs and partnerships, ICMA has advanced essential thought leadership on issues such as pollution mitigation, financial and economic stability, education, and urban planning in over 70 countries since its founding. Through existing programs, ICMA has already enabled 3,000 individuals in the Philippines to utilize climate information to improve resiliency and provided 60 youth in Bangladesh with mentorship to develop conflict-management and other skills.

These international collaborations are the catalyst for this new global strategy, which will support further strategic commitment to sharing ICMA’s resources and expertise with local governments around the world.

“In an ever more globalized world, we have so much to learn from each other as we strive to serve our communities,” said Troy Brown, President of ICMA. “We’re excited to see the types of thought leadership and new ideas that emerge from a more direct international emphasis on government administration across the globe.”

In our increasingly globalized society, many of the most pressing, complex issues facing local governments, from climate change to public health, transcend borders. There are over 500,000 local governments around the globe that employ millions of individuals, representing a significant opportunity to share ICMA’s educational opportunities and expertise.

About ICMA
The International City/County Management Association (ICMA), advances professional local government management worldwide through leadership, management, innovation, and ethics. ICMA provides member support; publications; data and information; peer and results-oriented assistance; and training and professional development to more than 12,000 city, town, and county experts and other individuals and organizations throughout the world. The management decisions made by ICMA’s members affect millions of individuals living in thousands of communities, from small villages and towns to large metropolitan areas. ICMA has gathered more data on local government than any organization except the federal government, spanning a broad spectrum from economic development to local government innovation.

Media contact:

Marykate Cary Mattiello

mcary@groupgordon.com

212-784-5708

Crane trained with AI technology performs automated point-to-point operation while suppressing the load sway.

TOKYO, Sept. 07, 2022 (GLOBE NEWSWIRE) — DeepX, Inc. (Headquarters: Bunkyo-ku, Tokyo, CEO: Kaoru Nasuno, hereinafter DeepX) and Tadano Ltd. (Headquarters: Takamatsu City, Kagawa Prefecture, President: Toshiaki Ujiie, hereinafter Tadano) have released the progress of a joint research project of crane automation utilizing AI technology.

Introduction movie of DeepX’s crane automation project can be found here: https://youtu.be/MHR4vxtgCCU

Background and purpose of this project

Cranes are general-purpose lifting equipment widely used in construction industries. Crane operators must operate multiple levers simultaneously while checking the position of the load visually. In addition, cranes are affected by the boom deflection and wind, so it takes a long time to become a proficient crane operator. On the other hand, the number of skilled crane operators in Japan is declining due to the aging population. The aim of this joint R&D project is to improve safety at work sites by simplifying and automating mobile crane operations by utilizing AI technologies.

Crane automation and its technical approach

Mobile cranes are known to be one of the most difficult machines to operate on construction sites.  Slewing and elevating motion in mobile cranes typically generates undesirable two-dimensional load-sway; therefore, crane operators must be highly skilled to suppress this sway upon completion of the point-to-point crane maneuver. DeepX and Tadano have therefore developed a control algorithm based on AI technology, levaredging simulator environment for controller optimization. Using this algorithm, the operator can safely and accurately move the load to the desired position while suppressing load sway.

Future prospects

DeepX will continue to work with Tadano to challenge more complex operations and further advance the technology for mobile crane automation. DeepX will also aim to apply this technology to various types of cranes in a wide range of industries.

About DeepX

DeepX is an AI startup that has its roots in the Matsuo Laboratory at the University of Tokyo with the mission of “Automating Any Machine and Innovating Global Industries”. By automating any kind of machine and promoting the automation of a wide range of manual work using various technologies including AI, DeepX aims to solve problems such as labor and skilled worker shortages as well as excessive staff workloads, which are significant challenges to many industries.

Established:  April 22, 2016

Business: Support for automation of machinery and field operations, business development using AI technology, software development, and R&D

URL: https://www.deepx.co.jp/

About the Tadano Group

Since Tadano developed Japan’s first hydraulic truck crane in 1955, the company has grown globally, while constantly striving to implement our Corporate Philosophy of Creation, Contribution, and Cooperation. The Tadano Group delivers our Core Values – Safety, Quality, and Efficiency Based on Compliance (C+SQE) – in each and every one of our products and services.

URL: https://www.tadano.com/

Contact

info@deepx.co.jp

Related Images

Image 1: Mobile crane

Crane used in this project and its simulation environment

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Mobile crane

Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon in China

ST. GALLEN, Switzerland, Sept. 07, 2022 (GLOBE NEWSWIRE) — Neovii Pharmaceuticals AG (“Neovii”), a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Stock Code: 600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group deep-rooted in China, have entered into an exclusive agreement (the “Agreement”), under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii’s Grafalon® (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® to Fosun Pharma Industry.

The parties’ aim is to firstly strengthen Grafalon’s position in the field of transplantation medicine in China, in which it is already approved for marketing and included in China’s National Reimbursement Drug List. Further, the Agreement entails clinical development to expand Grafalon’s regulatory approval in China to the prevention of Graft versus Host Disease following allogenic stem cell transplantation (“SCT”), so as to align its approved usages in China with those in Europe and other countries worldwide. Additional objective is to evolve Grafalon’s usages from transplantation medicine to auto-immune and onco-hematology conditions, where Grafalon has the potential to positively-transform the lives of patients suffering from severe diseases with high unmet need. The Agreement also sets the foundation to expand the cooperation to additional products of Neovii, starting from NB-15, a novel, clinical-stage therapy that is under development for the treatment of Mitochondrial neurogastrointestinal encephalomyo-pathy (MNGIE), an ultra-rare, devastating and uniformly fatal disorder.

Wen Deyong, CEO of Fosun Pharma said: “Grafalon has an excellent effect in solid organ transplant recipients, especially those with a high risk of rejection. We are very pleased to be working with Neovii to bring this product into China. Going forward, we will leverage our advantages in nephrology and hematology and more areas to make the medicines accessible to patients and benefiting more Chinese patients.”

Dr. Christian Loss, CEO of Neovii said: “As a leading global pharmaceutical and healthcare industry group in China, Fosun Pharma is the ideal partner to develop and commercialize Grafalon in China. This collaboration positions Grafalon for sustained growth in China and advances the development in stem cell transplant and beyond as in devastating auto-immune and other diseases. We look forward to working with Fosun Pharma to bring Grafalon to more patients in-need in China.”

Neovii was supported by Marshal Ma of Link China Pharma Solutions (Cambridge, UK based), who gave valuable help in the negotiation process.

About Grafalon
Grafalon® (Rabbit anti-human T-lymphocyte globulin, ATLG, formerly also known as “ATG-Fresenius S” and “ATG-F”) was developed by Neovii and is used to improve patients’ outcomes in transplantation medicine in more than 50 countries and, in selected countries, also to treat aplastic anemia. With more than 250,000 treated patients, 30 years of clinical experience and leadership position in many countries, Grafalon® has transformed the way transplant teams manage the care of their patients and is uniquely addressing significant unmet needs. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements. For more details, please refer to the approved product information for each respective jurisdiction.

About Neovii
Neovii is a Swiss-based, global, fully integrated, rapidly-growing, commercial-stage, specialty-care biopharmaceutical company with sales in more than 50 countries. Neovii has a proven track-record of over more than three decades in pursuing its mission to bring novel life-transforming therapies to patients that suffer from devastating conditions with significant unmet medical needs. Neovii is a member of the Neopharm Group that, through its family of companies, is engaged in research, development and commercialization of a broad range of products and added-value services in three major segments: Pharmaceutical, Medical and Consumer Healthcare, with revenues exceeding $500 million and more than 1,000 employees worldwide.

Cautionary Note on Forward-Looking Statements
This press release, the statements herein or those of representatives and partners of Neovii related thereto contain, or may contain, among other things, certain “forward-looking statements”. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Neovii’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of Neovii’s management and are subject to significant risks and uncertainties. Actual results (including, without limitation, those relating to the SCT approval in China) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Neovii’s control). Neovii undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information, please visit www.neovii.com
Neovii Pharmaceuticals AG
Zürcherstrasse 19
8640 Rapperswil
Switzerland
Tel: +41 55 210 05 00
Email: belen.podesta@neovii.com

About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

For more information, please visit Fosun’s official website: www.fosunpharma.com.

Related Images

1: Neovii and Fosun Logo

Neovii and Fosun Logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Neovii and Fosun Logo

วอลแทม แมสซาชูเซตส์ และ เซี่ยงไฮ จีน, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma บริษัทชีวเภสัชภัณฑ์ระดับโลกซึ่งมุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและจำหน่ายการรักษาด้วยภูมิคุ้มกันบำบัดสำหรับผู้ป่วยที่ต้องการความช่วยเหลือทั่วโลก ได้ประกาศแต่งตั้งนายแพทย์ Simon Lowry เป็นประธานเจ้าหน้าที่ฝ่ายการแพทย์ของบริษัท นายแพทย์ Lowry ได้นำความเชี่ยวชาญทางคลินิกในวงกว้างมาเป็นเวลากว่า 20 ปีในการออกแบบและดำเนินการโปรแกรมทางคลินิกตั้งแต่ระยะเริ่มต้นจนถึงระยะสุดท้ายมายัง Zenas ซึ่งเขาจะเป็นผู้นำด้านคลินิก กิจการทางการแพทย์ และการดูแลด้านเภสัชกรรมระดับโลกของบริษัท

“เรามีความยินดีเป็นอย่างยิ่งที่ได้ต้อนรับนายแพทย์ Lowry มายัง Zenas ในช่วงเวลาสำคัญนี้ของบริษัท ซึ่งเป็นช่วงที่เราเริ่มการทดลองลงทะเบียนที่สามสองขั้นตอนสำหรับ obexelimab ผู้สมัครผลิตภัณฑ์หลักของเราในไตรมาสที่สี่ของปีนี้ และเริ่มการทดลองทางคลินิกครั้งแรกในมนุษย์ เพื่อโครงการไปป์ไลน์หลายโครงการ” นายแพทย์ดุษฎีบัณฑิต (M.D., Ph. ) Hua Mu ประธานเจ้าหน้าที่บริหารของ Zenas กล่าว “ทั้งความเป็นผู้นำซึ่งเป็นที่ประจักษ์แล้ว ภูมิหลังด้านการพัฒนาทางคลินิกในวงกว้าง และประสบการณ์การทดลองทางคลินิกทั่วโลกที่กว้างขวางของนายแพทย์ Lowry จะเสริมสร้างความสามารถของเราในการดำเนินการตามภารกิจในการเปลี่ยนแปลงชีวิตผู้ป่วยที่มีความต้องการทางการแพทย์ที่ยังไม่ได้รับการตอบรับโดยนำเสนอการรักษาด้วยภูมิคุ้มกันบำบัดที่ดีที่สุดให้กับผู้ป่วย”

นายแพทย์ Simon Lowry กล่าวเสริมว่า “มีผู้ป่วยโรคภูมิคุ้มกันทำลายตนเองและโรคหายากจำนวนมากที่ต้องการตัวเลือกการรักษาใหม่ที่มีประสิทธิภาพ ทีมงาน Zenas ที่มากด้วยประสบการณ์และมีความสามารถได้สร้างความก้าวหน้าอันน่าประทับใจในการขับเคลื่อนบริษัทในระยะเวลาอันสั้น และผมตั้งตารอที่จะเป็นผู้นำความก้าวหน้าอย่างต่อเนื่องของโปรแกรมทางคลินิกของ Zenas ผ่านการค้าควบคู่ไปกับการขยายไปป์ไลน์ของบริษัทในด้านนวัตกรรมต่อไปครับ”

นายแพทย์ Lowry เป็นแพทย์ที่มีประสบการณ์มากว่า 20 ปีในบริษัทเภสัชกรรมและเทคโนโลยีชีวภาพขนาดใหญ่และเพิ่งเริ่มเติบโต ซึ่งกำกับดูแลโครงการพัฒนาที่ประสบความสำเร็จ ทีมผู้นำด้านการแพทย์และคลินิก และทำงานร่วมกันกับหน่วยงานกำกับดูแลในด้านการแพทย์ต่าง ๆ ซึ่งรวมถึงโรคข้อ ภูมิคุ้มกันวิทยา และจักษุวิทยา ก่อนร่วมงานกับ Zenas นั้น นายแพทย์ Lowry เคยเป็นหัวหน้าเจ้าหน้าที่การแพทย์ของ Kinevant Science ซึ่งเป็นบริษัทชีวเภสัชภัณฑ์ขั้นมีอาการของโรคที่มุ่งเน้นการรักษาโรคอักเสบและโรคภูมิคุ้มกันทำลายตนเองที่พบได้ยาก นายแพทย์ Lowry เคยเป็นหัวหน้าฝ่ายวิจัยและพัฒนาด้านภูมิคุ้มกันวิทยาที่ Roivant Sciences ซึ่งเป็นผู้นำด้านภูมิคุ้มกันวิทยาในขั้นตอนการพัฒนาทั้งหมดไปสู่การพัฒนาทางคลินิก และทำหน้าที่เป็นสมาชิกคนสำคัญของทีมผู้นำ นอกจากนี้ เขายังดำรงตำแหน่งหัวหน้าเจ้าหน้าที่การแพทย์ที่ Sun Pharma North America ซึ่งเขาได้รับผิดชอบด้านการรักษาสี่แขนง (วิทยาภูมิคุ้มกันและโรคผิวหนัง จักษุวิทยา ประสาทวิทยา และมะเร็งวิทยา) และเป็นผู้นำด้านการพัฒนาและการทำงานทางการแพทย์ทุกด้าน (รวมถึงการพัฒนาทางคลินิก ข้อมูลทางการแพทย์ การแพทย์ภาคสนาม HEOR สิ่งพิมพ์/การสื่อสารทางการแพทย์และการดำเนินงาน) ในช่วงเริ่มต้นของการทำงาน เขาเคยทำงานที่ Novartis ซึ่งเขาดำรงตำแหน่งรองประธาน หัวหน้าฝ่ายกิจการการแพทย์ระดับโลก ภูมิคุ้มกันวิทยาและโรคผิวหนัง และไฟเซอร์ ซึ่งเขาทำหน้าที่ซึ่งมีความรับผิดชอบที่เพิ่มขึ้น ซึ่งรวมถึงได้ดำรงตำแหน่งรองประธานผู้นำกลุ่มกิจการการแพทย์ด้านเนื้องอกวิทยาด้วย

ก่อนประกอบอาชีพด้านเภสัชกรรม/เทคโนโลยีชีวภาพ นายแพทย์ Lowry เคยทำงานด้านอายุรศาสตร์ในสถาบันต่าง ๆ ในสหราชอาณาจักรและออสเตรเลีย เขาสำเร็จการศึกษาระดับปริญญาตรีจาก Trinity Hall, Cambridge University, UK และปริญญาทางการแพทย์ MB BChir จาก Cambridge University School of Clinical Medicine

ข้อมูลเกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและจำหน่ายการรักษาด้วยภูมิคุ้มกันบำบัดให้แก่ผู้ป่วยทั่วโลก ด้วยการพัฒนาทางคลินิกและการปฏิบัติการในสหรัฐอเมริกาและจีน ทำให้ Zenas ได้พัฒนานวัตกรรมการรักษาเชิงลึกอย่างรวดเร็ว ซึ่งยังคงเติบโตอย่างต่อเนื่องผ่านกลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จของเรา ทีมผู้นำที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราขับเคลื่อนความเป็นเลิศในการดำเนินงานเพื่อนำเสนอการบำบัดต่าง ๆ ที่มีความเป็นไปได้ที่จะก่อให้เกิดการปลี่ยนแปลงได้เพื่อที่จะปรับปรุงชีวิตของผู้ที่เผชิญกับโรคภูมิต้านทานเนื้อเยื่อของตนเองและโรคที่พบได้ยากต่าง ๆ สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma กรุณาเยี่ยมชม www.zenasbio.com และติดตามเราบน ทวิตเตอร์ ได้ที่ @ZenasBioPharma และ ลิงกต์อิน

ติดต่อนักลงทุนและสื่อ:Joe Farmer

Zenas BioPharma

IR@zenasbio.com

• The completion of the ISA’s review of the Collector Test Environmental Impact Statement (EIS) paves the way for TMC subsidiary, Nauru Ocean Resources Inc (NORI), to conduct its planned pilot collection system trials on its NORI-D exploration area in the Clarion Clipperton Zone of the Pacific Ocean beginning later this month.
• An integral part of the ISA’s regulatory and permitting process, the trials will be monitored by independent scientists from a dozen leading research institutions, providing critical environmental impact data to inform NORI’s application to the ISA for an exploitation contract.
• Upcoming integrated nodule collection system trials will mark the first such trials to be conducted in the CCZ since the 1970s.

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) — The Metals Company (Nasdaq: TMC) (the “Company” or “TMC”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today announced that the International Seabed Authority has completed its review of the Environmental Impact Statement (EIS) and Environmental Monitoring and Management Plan (EMMP) submitted by its subsidiary, Nauru Ocean Resources Inc (NORI), and recommended that it proceed with its forthcoming collector test.

The conclusion of the International Seabed Authority’s review process allows NORI to proceed with its planned integrated pilot collection system trials in its NORI-D exploration contract area in the Clarion Clipperton Zone (CCZ) of the Pacific Ocean. NORI’s offshore strategic partner Allseas will test a system consisting of a prototype nodule collector at the seafloor and the riser system to bring nodules to the surface production vessel, Hidden Gem. Approximately 3,600 tonnes of polymetallic nodules are expected to be collected during the trial beginning later this month with an expected conclusion in the fourth quarter of 2022.

The trials will be monitored by independent scientists from a dozen leading research institutions around the world who will analyse the environmental impacts of both the pilot nodule collector vehicle and the nodule riser system. The data collected, together with many terabytes of existing baseline data collected by NORI throughout 16 offshore campaigns, will form the basis of NORI’s application to the International Seabed Authority for an exploitation contract.

Gerard Barron, CEO and Chairman of The Metals Company, commented: “Our team has worked tirelessly to produce an EIS, EMMP and integrate constructive feedback and recommendations from the ISA’s Legal and Technical Commission. With this green light from the ISA, the team of world-class engineers from Allseas and scientists from some of the world’s leading deep-sea research institutions that we’ve brought together can begin technology trials and our impact monitoring campaign. We have a couple of exciting and no doubt challenging months ahead of us. The environmental and operational data and insights from these trials will be an important step in ensuring the safe and efficient collection of polymetallic nodules to supply critical battery materials for the clean energy transition.”

Following the submission of its EIS to the International Seabed Authority in July 2021, the Republic of Nauru, the sponsoring state of NORI, undertook an open stakeholder consultation program to solicit comments and feedback. Based upon this feedback and with over 600 comments received, an updated EIS was submitted to the ISA in March 2022. Barron added: “I would like to thank the ISA’s Legal and Technical Commission for their detailed review and feedback which, together with stakeholder comments, has improved the EIS and demonstrates the robustness of the ISA’s regulatory review process.”

Previously, TMC and Allseas announced successful trials of the nodule collector vehicle in deep-water in the Atlantic [see video] as well as harbor wet-test commissioning and shallow-water drive tests in the North Sea.

Development of technologies to collect polymetallic nodules first began in the 1970s when oil, gas and mining majors including Shell, Rio Tinto (Kennecott) and Sumitomo successfully conducted pilot test work in the CCZ, collecting over fifteen hundred tons of nodules. More recently, contractors BGR and GSR conducted several trials of prototype nodule collector vehicles in deep water, and NORI’s forthcoming tests mark the first time this century that an integrated collection system – including a nodule riser – would be trialled in the CCZ.

About The Metals Company

The Metals Company is an explorer of lower-impact battery metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for the clean energy transition with the least possible negative environmental and social impact and (2) accelerate the transition to a circular metal economy. The Company through its subsidiaries holds exploration and commercial rights to three polymetallic nodule contract areas in the Clarion Clipperton Zone of the Pacific Ocean regulated by the International Seabed Authority and sponsored by the governments of Nauru, Kiribati and the Kingdom of Tonga.

More Info 
Media | media@metals.co
Investors | investors@metals.co

Forward Looking Statements

Certain statements made in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. The forward-looking statements contained in this press release include, without limitation, statements regarding the approval and review of our Environmental Impact Statement (EIS) by the international seabed authority, the development and use of an ecosystem-based management and monitoring plan (EMMP) as well as the design, use and accuracy of any technology developed by TMC and its partners, agents and/or service providers to support its operations. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside TMC’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: regulatory uncertainties and the impact of government regulation and political instability on TMC’s resource activities; changes to any of the laws, rules, regulations or policies to which TMC is subject; the impact of extensive and costly environmental requirements on TMC’s operations; environmental liabilities; the impact of polymetallic nodule collection on biodiversity in the Clarion Clipperton Zone and recovery rates of impacted ecosystems; TMC’s ability to develop minerals in sufficient grade or quantities to justify commercial operations; the lack of development of seafloor polymetallic nodule deposit; uncertainty in the estimates for mineral resource calculations from certain contract areas and for the grade and quality of polymetallic nodule deposits; risks associated with natural hazards; uncertainty with respect to the specialized treatment and processing of polymetallic nodules that TMC may recover; risks associated with collection, development and processing polymetallic nodules; risks associated with TMC’s limited operating history; the impact of the COVID-19 pandemic; risks associated with TMC’s intellectual property and the validity, use and ownership of any new technology or intellectual property subsisting therein; and other risks and uncertainties indicated from time to time in the Company’s Form 10K, dated and filed with the U.S. Securities and Exchange Commission (SEC) on March 25, 2022 as well as the Company’s Form 10Q filed with the SEC on August 15, 2022, including those under “Risk Factors” therein, and in TMC’s other future filings with the SEC. TMC cautions that the foregoing list of factors is not exclusive. TMC cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. TMC does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based except as required by law.